MedTrace Logo

Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication

NCT00841854 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 199

Last updated 2016-12-06

No results posted yet for this study

Summary

At present, triple therapy are recommended by various guidelines for the treatment of Helicobacter pylori (H. pylori) infection. Recent studies have shown worldwide high treatment failure rates with one week first line clarithromycin based triple therapy necessitating salvage strategy to eradicate H. pylori in primary treatment failure. However, the exact duration of bismuth based second line treatment is not determined. Therefore, the investigators performed this study to evaluate the eradication rate of 1 or 2-week quadruple regimen as a second-line therapy.

Conditions

  • Helicobacter Infection

Interventions

DRUG

pantoprazole

pantoprazole 40mg bid

DRUG

bismuth

bismuth 300mg qid

DRUG

metronidazole

metronidazole 500mg tid

DRUG

tetracycline

tetracycline 500mg qid

Sponsors & Collaborators

  • Inje University

    collaborator OTHER

  • Pacific Pharmaceuticals

    collaborator INDUSTRY

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Hwoon-Yong Jung, M.D · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-05-31
Completion
2010-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00841854 on ClinicalTrials.gov